Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients

Annals of Pharmacotherapy

Volumn 45, Issue 9, 2011, Pages

  Gabardi, Steven ^a   Catella, Jennifer ^a   Martin, Spencer T ^b   Perrone, Ronald ^c   Chandraker, Anil ^a   Magee, Colm C ^d   McDevitt Potter, Lisa M ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d BEAUMONT HOSPITAL   (Ireland)

Author keywords

Basiliximab; Maintenance immunosuppression; Renal transplant

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN;

ABSENCE OF SIDE EFFECTS; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; PRIORITY JOURNAL; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; TIME FACTORS;

EID: 80052487348     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q019     Document Type: Article

References (19)

1. Andreoni KA, Brayman KL, Guidinger MK, Sommers CM, Sung RS. Kidney and pancreas transplantation in the United States, 1996-2005. Am J Transplant 2007;7:1359-75.
2. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:2715-29.
3. Vincenti F, Kirk AD. What's next in the pipeline. Am J Transplant 2008; 8:1972-81.
4. Yabu JM, Vincenti F. Novel immunosuppression: small molecules and biologics. Semin Nephrol 2007;27:479-86.
5. Package insert. Simulect (basiliximab). East Hanover, NJ: Novartis Pharmaceuticals Corp., September 2005.
6. Package insert. Zenapax (daclizumab). Nutley, NJ: Roche Pharmaceuticals, September 2005.
7. Food and Drug Administration. Important drug information. Updated September 2009. www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM194907.pdf (accessed 2011 Apr 9).
8. Arias M, Campistol JM, Vincenti F. Evolving trends in induction therapy. Transplant Rev (Orlando) 2009;23:94-102.
9. Onrust SV, Wiseman LR. Basiliximab. Drugs 1999;57:207-13.
10. Mentre F, Kovarik J, Gerbeau C. Constructing a prediction interval for time to reach a threshold concentration based on a population pharmacokinetic analysis: an application to basiliximab in renal transplantation. J Pharmacokinet Biopharm 1999;27:213-30.
11. Kovarik J, Wolf P, Cisterne JM, et al. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation 1997;64:1701-5.
12. Cantarovich M, Metrakos P, Giannetti N, Cecere R, Barkun J, Tchervenkov J. Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor "holiday" in solid organ transplant patients with acute renal dysfunction. Transplantation 2002;73:1169-72.
13. Anselm A, Cantarovich M, Davies R, Grenon J, Haddad H. Prolonged basiliximab use as an alternative to calcineurin inhibition to allow renal recovery late after heart transplantation. J Heart Lung Transplant 2008; 27:1043-5.
14. Cantarovich M, Giannetti N, Routy JP, Cecere R, Barkun J. Long-term immunosuppression with anti-CD25 monoclonal antibodies in heart transplant patients with chronic kidney disease. J Heart Lung Transplant 2009;28:912-8.
15. Kumar A, Khan S, Malat G, Culkin C, Sustento-Reodica N. Outcome of calcineurin inhibitor (CNI) withdrawal and conversion to triple therapy with chronic basiliximab infusion, sirolimus (SRL) and enteric coated mycophenolic sodium (EC-MPS) in kidney recipients with biopsy proven moderate/severe chronic allograft nephropathy (CAN) and graft dysfunction (abstract 1475). American Transplant Congress, San Francisco, CA, 2007.
16. Nussenblatt RB, Thompson DJ, Li Z, et al. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for sub- cutaneous administration. J Autoimmun 2003;21:283-93.
17. Study to evaluate the safety of chronic administration of Simulect to subjects receiving a first kidney transplant. Updated March 24, 2011. www.clinicaltrials.gov/ct2/show/NCT00928811?term=basiliximab&rank=1 (accessed 2011 Mar 24).
18. Safety and efficacy of basiliximab in calcineurin inhibitor intolerant long-term kidney transplant recipients treated with mycophenolic acid and steroids. Updated October 15, 2009. www.clinicaltrials.gov/ct2/show/NCT00284947?term=basiliximab&rank=2 (accessed 2011 Mar 24).
19. 2010 Red book; pharmacy's fundamental reference. Montvale, NJ: Thomson Healthcare, Inc, 2010.